FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to a bispecific antibody specifically binding human CEACAM5 and CD3ε person. Said antibody comprises a binding fragment specifically binding human CEACAM5 and a second binding fragment specifically binding CD3ε person. Present invention also relates to the use of said antibody for treating solid tumours expressing CEA in vivo, a pharmaceutical composition containing it, a polynucleotide, a vector and a cell for producing said antibody.
EFFECT: invention provides obtaining novel effective bispecific anti-CEAxCD3.
14 cl, 18 dwg, 7 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| ADAM9-BINDING MOLECULES AND THEIR APPLICATION METHODS | 2017 |
|
RU2783619C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
| ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF | 2020 |
|
RU2831838C2 |
| BISPECIFIC ANTI-EGFR/ANTI-4-1BB ANTIBODY AND USE THEREOF | 2020 |
|
RU2831836C2 |
| IMMUNE TOLERANCE INDUCING ANTIBODIES, INDUCED LYMPHOCYTES AND THERAPEUTIC AGENT/METHOD OF CELL THERAPY USING INDUCED LYMPHOCYTES | 2019 |
|
RU2816592C2 |
| IMPROVED ANTI-FLT3 ANTIGEN-BINDING PROTEINS | 2019 |
|
RU2830982C2 |
